86 related articles for article (PubMed ID: 20629977)
21. Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study.
Niguma T; Mimura T; Tutui N
J Hepatobiliary Pancreat Surg; 2005; 12(3):249-53. PubMed ID: 15995815
[TBL] [Abstract][Full Text] [Related]
22. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
23. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis.
Neef M; Ledermann M; Saegesser H; Schneider V; Reichen J
J Hepatol; 2006 Dec; 45(6):786-96. PubMed ID: 17050028
[TBL] [Abstract][Full Text] [Related]
24. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
Chuah B; Lim R; Boyer M; Ong AB; Wong SW; Kong HL; Millward M; Clarke S; Goh BC
Acta Oncol; 2007; 46(2):234-8. PubMed ID: 17453375
[TBL] [Abstract][Full Text] [Related]
25. Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence.
Castroagudín JF; Molina E; Tomé S; Otero E; Rodríguez M; Varo E
Transplant Proc; 2009 Apr; 41(3):1003-4. PubMed ID: 19376410
[TBL] [Abstract][Full Text] [Related]
26. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience.
Zimmerman MA; Trotter JF; Wachs M; Bak T; Campsen J; Wright F; Steinberg T; Bennett W; Kam I
Transpl Int; 2007 Sep; 20(9):747-53. PubMed ID: 17565579
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA
Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
[TBL] [Abstract][Full Text] [Related]
28. Involvement of mTOR and survivin inhibition in tamoxifen-induced apoptosis in human hepatoblastoma cell line HepG2.
Guo R; Wang T; Shen H; Ge HM; Sun J; Huang ZH; Shu YQ
Biomed Pharmacother; 2010 Apr; 64(4):249-53. PubMed ID: 19931998
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
[TBL] [Abstract][Full Text] [Related]
30. Effects of rapamycin in liver transplantation.
Chen YB; Sun YA; Gong JP
Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):25-8. PubMed ID: 18234634
[TBL] [Abstract][Full Text] [Related]
31. Rapamycin inhibits proliferation and migration of hepatoma cells in vitro.
Shirouzu Y; Ryschich E; Salnikova O; Kerkadze V; Schmidt J; Engelmann G
J Surg Res; 2010 Apr; 159(2):705-13. PubMed ID: 19482307
[TBL] [Abstract][Full Text] [Related]
32. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
Huynh H
Cancer; 2010 Mar; 116(5):1315-25. PubMed ID: 20101735
[TBL] [Abstract][Full Text] [Related]
33. mTOR inhibitors in hematologic malignancies.
Dancey JE
Clin Adv Hematol Oncol; 2003 Jul; 1(7):419-23. PubMed ID: 16258427
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
[TBL] [Abstract][Full Text] [Related]
35. Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro.
Zhang JF; Liu JJ; Lu MQ; Cai CJ; Yang Y; Li H; Xu C; Chen GH
Transpl Immunol; 2007 Apr; 17(3):162-8. PubMed ID: 17331842
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of hepatocellular carcinoma.
Greten TF; Manns MP; Korangy F
J Hepatol; 2006 Dec; 45(6):868-78. PubMed ID: 17046096
[No Abstract] [Full Text] [Related]
37. Sirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient.
Ho CM; Huang SF; Hu RH; Ho MC; Wu YM; Lee PH
Clin Transplant; 2010; 24(1):127-32. PubMed ID: 19919613
[TBL] [Abstract][Full Text] [Related]
38. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
Kneteman NM; Oberholzer J; Al Saghier M; Meeberg GA; Blitz M; Ma MM; Wong WW; Gutfreund K; Mason AL; Jewell LD; Shapiro AM; Bain VG; Bigam DL
Liver Transpl; 2004 Oct; 10(10):1301-11. PubMed ID: 15376305
[TBL] [Abstract][Full Text] [Related]
39. Chemolipiodolization and prostaglandin E1 administration with use of hepatic arterial infusion port for the treatment of hepatocellular carcinoma and liver cirrhosis.
Kakizoe S; Kakizoe K; Kakizoe Y; Kakizoe H; Kakizoe T; Kakizoe S
Hepatogastroenterology; 1996; 43(11):1377-82. PubMed ID: 8908577
[TBL] [Abstract][Full Text] [Related]
40. mTOR inhibitors for hepatocellular cancer: a forward-moving target.
Treiber G
Expert Rev Anticancer Ther; 2009 Feb; 9(2):247-61. PubMed ID: 19192962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
